Literature DB >> 11999911

Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients.

Kemal Yazici1, Aylin Ertekin Yazici, Bilgen Taneli.   

Abstract

BACKGROUND: Thyrotropin-releasing hormone (TRH) test and Dexamethasone Suppression Test (DST) are two neuroendocrine tests that have been extensively used in an attempt to predict treatment response and outcome in schizophrenia. The objectives of this study were to investigate (1) the relationship between TRH test and DST and various psychiatric symptoms and (2) the potential value of these tests in prediction of short-term outcome in schizophrenic patients.
METHODS: TRH test and DST were administered to 58 patients with schizophrenia. All patients were evaluated with a battery of rating scales before neuroendocrine test procedures and at regular intervals for 1 year. Patients were divided into two groups as remitted (RP; n = 30) and nonremitted patients (NRP; n = 28). Baseline results of these two groups were compared with each other and 30 healthy controls.
RESULTS: Basal levels of total T3 (T3T) and free T3 (T3F) were higher in RP group than controls. Basal prolactin (PRL) level was higher in RP group, but not in NRP, compared to controls. Basal growth hormone (GH) and thyroid-stimulating hormone (TSH) levels of NRP were significantly higher than those of RP. DST nonsuppression was observed at a significantly higher rate in RP than NRP and control group. Blunted TSH response rate in RP group was higher significantly compared to other two groups.
CONCLUSIONS: The data implicate that higher basal TSH and GH levels may be associated with a poorer treatment response, whereas higher total and free T3 levels, a blunted TSH response to TRH and nonsuppression on the DST may indicate a better response in schizophrenics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999911     DOI: 10.1016/s0278-5846(01)00311-6

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  8 in total

1.  Abnormal glucocorticoid receptor mRNA and protein isoform expression in the prefrontal cortex in psychiatric illness.

Authors:  Duncan Sinclair; Shan Yuan Tsai; Heng Giap Woon; Cynthia Shannon Weickert
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

2.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

3.  Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics.

Authors:  Moses O Akiibinu; Omobola A Ogundahunsi; Ebenezer O Ogunyemi
Journal:  BMC Res Notes       Date:  2012-03-31

4.  Revisiting thyroid hormones in schizophrenia.

Authors:  Nadine Correia Santos; Patrício Costa; Dina Ruano; António Macedo; Maria João Soares; José Valente; Ana Telma Pereira; Maria Helena Azevedo; Joana Almeida Palha
Journal:  J Thyroid Res       Date:  2012-03-26

5.  Levothyroxine Augmentation in Clozapine Resistant Schizophrenia: A Case Report and Review.

Authors:  Ruohollah Seddigh; Somayeh Azarnik; Amir-Abbas Keshavarz-Akhlaghi
Journal:  Case Rep Psychiatry       Date:  2015-05-11

6.  Thyroid axis function after in-patient treatment of acute psychosis with antipsychotics: a naturalistic study.

Authors:  Robertas Bunevicius; Vesta Steibliene; Arthur J Prange
Journal:  BMC Psychiatry       Date:  2014-10-08       Impact factor: 3.630

7.  Redefining the Cut-Off Ranges for TSH Based on the Clinical Picture, Results of Neuroimaging and Laboratory Tests in Unsupervised Cluster Analysis as Individualized Diagnosis of Early Schizophrenia.

Authors:  Natalia Śmierciak; Marta Szwajca; Tadeusz J Popiela; Amira Bryll; Paulina Karcz; Paulina Donicz; Aleksander Turek; Wirginia Krzyściak; Maciej Pilecki
Journal:  J Pers Med       Date:  2022-02-09

8.  Level of thyroid-stimulating hormone (TSH) in patients with acute schizophrenia, unipolar depression or bipolar disorder.

Authors:  Adam Wysokiński; Iwona Kłoszewska
Journal:  Neurochem Res       Date:  2014-04-11       Impact factor: 3.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.